Filing Details
- Accession Number:
- 0001209191-23-010050
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-16 16:14:12
- Reporting Period:
- 2023-02-14
- Accepted Time:
- 2023-02-16 16:14:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-02-14 | 800 | $295.84 | 81,203 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-14 | 901 | $296.85 | 80,302 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-14 | 560 | $298.14 | 79,742 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-14 | 2,003 | $299.13 | 77,739 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-14 | 1,734 | $300.09 | 76,005 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-14 | 400 | $300.89 | 75,605 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $295.84 (range $295.34 to $296.20).
- Open market sales reported on this line occurred at a weighted average price of $296.85 (range $296.49 to $297.30).
- Open market sales reported on this line occurred at a weighted average price of $298.14 (range $297.59 to $298.57).
- Open market sales reported on this line occurred at a weighted average price of $299.13 (range $298.68 to $299.60).
- Open market sales reported on this line occurred at a weighted average price of $300.09 (range $299.73 to $300.70).
- Open market sales reported on this line occurred at a weighted average price of $300.89 (range $300.78 to $301.03).
Billionaire Hedge Funds
